Multivariate analysis of outcomes according to best response in the intent-to-treat population, in VMP and MP patients, by EBMT criteria
| . | Hazard ratio (95% CI) . | |
|---|---|---|
| Versus PR . | Versus < PR . | |
| TTP | ||
| Patients achieving CR | 0.45 (0.26-0.78), P = .004 | 0.31 (0.18-0.56), P = .0001 |
| Patients achieving PR | — | 0.69 (0.51, 0.95), P = .021 |
| TNT | ||
| Patients achieving CR | 0.48 (0.34-0.68), P = .0001 | 0.33 (0.22-0.47), P < .0001 |
| Patients achieving PR | — | 0.68 (0.54-0.85), P = .0008 |
| TFI | ||
| Patients achieving CR | 0.42 (0.30-0.60), P = .0001 | 0.27 (0.18-0.39), P < .0001 |
| Patients achieving PR | — | 0.63 (0.51-0.79), P < .0001 |
| OS | ||
| Patients achieving CR | 0.87 (0.56-1.36), P = .54 | 0.52 (0.33-0.82), P = .005 |
| Patients achieving PR | — | 0.60 (0.44-0.81), P = .0009 |
| . | Hazard ratio (95% CI) . | |
|---|---|---|
| Versus PR . | Versus < PR . | |
| TTP | ||
| Patients achieving CR | 0.45 (0.26-0.78), P = .004 | 0.31 (0.18-0.56), P = .0001 |
| Patients achieving PR | — | 0.69 (0.51, 0.95), P = .021 |
| TNT | ||
| Patients achieving CR | 0.48 (0.34-0.68), P = .0001 | 0.33 (0.22-0.47), P < .0001 |
| Patients achieving PR | — | 0.68 (0.54-0.85), P = .0008 |
| TFI | ||
| Patients achieving CR | 0.42 (0.30-0.60), P = .0001 | 0.27 (0.18-0.39), P < .0001 |
| Patients achieving PR | — | 0.63 (0.51-0.79), P < .0001 |
| OS | ||
| Patients achieving CR | 0.87 (0.56-1.36), P = .54 | 0.52 (0.33-0.82), P = .005 |
| Patients achieving PR | — | 0.60 (0.44-0.81), P = .0009 |
CI indicates confidence interval; CR, complete response; EBMT, European Group for Blood and Marrow Transplantation; OS, overall survival; PR, partial response; TFI, treatment-free interval; TNT, time to next therapy; TTP, time to progression; VMP, bortezomib-melphalan-prednisone; MP, melphalan-prednisone; and —, not applicable.